Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, ...

Shares of Vertex Pharmaceuticals plunged more than 14% to $404.89 after it release disappointing top-line results from its recently completed Phase II, randomized, double-blind, placebo-controlled ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

Company opts not to advance VX-993 into pivotal development after Phase II data show no statistically significant benefit ...

Vertex Pharmaceuticals ( VRTX) plunged after Q2 earnings and is now down 21% over the past year. The company has historically ...

Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.

Vertex Pharmaceuticals ( NASDAQ: VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet ...

Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and ...

Vertex Pharmaceuticals said on Monday it will not continue development of its experimental non-opioid painkiller as a solo ...

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company ...

Vertex Pharmaceuticals said Monday afternoon that its next-generation non-opioid pain reliever failed to significantly ...

In connection with earnings, Vertex announced topline results from the Phase 2 study evaluating the safety and efficacy of VX ...